Hira Bani Hani

Introduction HER2-positive breast cancer (HER2+ BC) constitutes 15–20% of all breast cancer cases,1 and is known for its aggressive tumor biology and poor prognosis without targeted therapy.2 The development of trastuzumab, a monoclonal antibody targeting HER2, has completely revolutionized the treatment for HER2+ BC patients, with dramatic improvement treatment outcomes.3 Further progress was achieved with the addition of pertuzumab to trastuzumab and cytotoxic chemotherapy, demonstrating...

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.